Business ❯Pharmaceutical Companies

Moderna

Revenue Source Covid-19 vaccines Financial Performance

FDA Approves Moderna's mRNA RSV Vaccine for Older Adults

The vaccine, mRESVIA, is the first mRNA-based RSV shot and the second product from Moderna to receive FDA approval.

Moderna's 2023 Sales Beat Estimates Despite Sharp Drop

Moderna Posts Large Q3 Loss With Weaker Vaccine Demand, Projects $4B in Sales for 2024, Investors Concerned